Skip to content
DataLookout
Menu

ROXI-PALISADENCT07318610

Reducing Adverse Vascular Outcomes With Factor XI Inhibition in Adult Participants With Peripheral Artery Disease

StatusRecruiting
PhasePhase 3
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 12 versions: 12 with changes below. See every version on ClinicalTrials.gov ↗

  1. Minor Study sites: 32 to 34
  2. Minor Trial sites expanded: 29 → 32 locations
  3. Minor Trial sites expanded: 20 → 29 locations
  4. Minor Study sites: 20 to 21
  5. Notable Eligibility criteria expanded, about 16 words
    • Trial sites expanded: 17 → 20 locations
    • Secondary endpoints: details revised at 2 of 26 entries
  6. Minor Trial sites expanded: 13 → 17 locationsv7
  7. Minor Study sites: 11 to 13v6
  8. Minor Study sites: 9 to 11
    • Start date changed from estimate of Jul 30, 2026 to Jul 10, 2026
    v5
  9. Notable Start date: May 29, 2026 to Jul 30, 2026
    • Trial sites expanded: 4 → 9 locations
    v4
  10. Minor Trial sites expanded: 1 → 4 locationsv3
  11. Notable Recruitment openedv2 Show 6 more changesShow less
    • Start date: Mar 31, 2026 to May 29, 2026
    • Eligibility criteria expanded, about 6 words
    • Primary completion pushed from May 5, 2029 to Aug 18, 2029
    • Study completion pushed from Aug 3, 2029 to Nov 16, 2029
    • Study sites: 0 to 1
    • Secondary endpoints revised (26)
  12. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Time-to-first occurrence of a major thrombotic vascular event, consisting of Acute Limb Ischemia (ALI), major amputation (above the ankle) of vascular etiology, Myocardial Infarction (MI), ischemic stroke, or Cardiovascular (CV) death
Timeframe: Approximately up to 42 months
Time-to-first occurrence of International Society of Thrombosis and Hemostasis (ISTH) major or Clinically Relevant Non-major (CRNM) bleeding
Timeframe: Approximately up to 42 months

Secondary (26)

Total (first and subsequent) occurrences of major thrombotic vascular events, consisting of ALI, major amputation (above the ankle) of vascular etiology, MI, ischemic stroke, or CV death
Time-to-first occurrence of an expanded thrombotic vascular event, consisting of ALI, major amputation (above the ankle) of vascular etiology, MI, ischemic stroke, CV death, unplanned index limb revascularization, or Venous Thromboembolism (VTE)
Time-to-first occurrence of ALI, major amputation (above the ankle) of vascular etiology, MI, ischemic stroke or coronary death
Time-to-first occurrence of vascular hospitalization for a coronary cerebrovascular, or peripheral event of thrombotic nature
Time-to-first occurrence of ALI, major amputation of vascular etiology, MI, ischemic stroke, or all-cause mortality
Show 21 moreShow less
Time-to-first occurrence of unplanned index limb revascularization for ischemia
Time-to-first occurrence of VTE
Time-to-all-cause mortality
Time-to-first occurrence of Major Adverse Limb Event (MALE)
Time-to-first occurrence of Major Adverse Cardiovascular Event (MACE)
Time-to-first occurrence of a major thrombotic vascular event or ISTH fatal/critical organ bleeding (net clinical benefit)
Time-to-first occurrence of Thrombolysis in Myocardial Infarction (TIMI) major bleeding
Occurrence of Treatment-Emergent Adverse Event (TEAEs)
Severity of TEAEs
Occurrence of Anti-Drug Antibody (ADA) to REGN7508 over time
Magnitude of ADA to REGN7508 over time
Occurrence of ADA to REGN9933 over time
Magnitude of ADA to REGN9933 over time
Concentrations of REGN7508 over time
Concentrations of REGN9933 over time
Change from baseline in activated Partial Thromboplastin Time (aPTT) over time
Change from baseline in Prothrombin Time (PT)/International Normalization Ratio (INR) over time
Total (first and subsequent) occurrences of expanded thrombotic vascular events
Time-to-first occurrence of a major thrombotic vascular event
Total (first and subsequent) occurrences of ALI, major amputation (above the ankle) of vascular etiology, MI, all-cause stroke, or CV death
Total (first and subsequent) occurrences of ALI, major amputation (above the ankle) of vascular etiology, MI, all-cause stroke, CV death, unplanned index limb revascularization, or VTE

Arms and interventions

Cohort 1Experimental
Cohort 2Experimental

Drugs: REGN7508, REGN9933, Placebo, Rivaroxaban

Sites

34 sites in 3 countries

United States 30, United Kingdom 3, Japan 1